SCHEMBL3290273

SCHEMBL3290273

COCCOC(=O)N1CCC(Oc2cccc(NC(=O)c3ccccc3-c3ccc(OCCOC)cc3)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
GAA P10253 2/20 0.48
MMP2 P08253 4/20 0.42
MMP3 P08254 4/20 0.42
MMP9 P14780 4/20 0.42
MMP8 P22894 4/20 0.42
MMP13 P45452 4/20 0.42
MMP1 P03956 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
MMP7 P09237 1/20 0.40
MLNR O43193 1/20 0.40
CYP3A4 P08684 1/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13329150 0.95 GAA (0.50) KDM4EGAAMMP13SMN1; SMN2MEN1
SCHEMBL3297214 0.91 TP53 (0.47) KDM4EGAAMAPT
SCHEMBL5144288 0.91 KDM4E (0.46) KDM4EGAAMMP2MMP3MMP9
SCHEMBL3289823 0.91 KDM4E (0.46) KDM4EGAAMMP2MMP3MMP9
SCHEMBL3292088 0.90 MTTP (0.48) KDM4EGAASMN1; SMN2ALDH1A1LMNA
SCHEMBL3290689 0.87 KDM4E (0.48) KDM4EGAASMN1; SMN2MEN1ALDH1A1
SCHEMBL3289514 0.86 GAA (0.47) KDM4EGAAALDH1A1LMNATSHR
SCHEMBL13329154 0.85 KDM4E (0.53) KDM4EGAASMN1; SMN2MEN1ALDH1A1
SCHEMBL3289504 0.85 GAA (0.60) KDM4EGAASMN1; SMN2MEN1ALDH1A1
Hydrochloric Acid SCHEMBL3314651 0.85 KDM4E (0.52) KDM4EGAASMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723358-B2 Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems MERCK PATENT GMBH (DE) 2010-05-25 US disclosed
US-7723358-B2 Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems MERCK PATENT GMBH (DE) 2010-05-25 US disclosed
US-7723358-B2 Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems MERCK PATENT GMBH (DE) 2010-05-25 US disclosed
US-20070254919-A1 Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems MERCK PATENT GMBH (DE) 2007-11-01 US disclosed
US-20070254919-A1 Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems MERCK PATENT GMBH (DE) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254919-A1 Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems GPR119, FABP4, LIPC KDM4E 1459/4885GAA 777/4885MMP2 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.